Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma

For security reasons, registration is required before you can use this feature.
* Indicates required field